Original news and analysis on international IP policy
The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria appointed Ambassador Mark Dybul, a former US Global AIDS Coordinator, as the new head of the organisation. Additionally, the Board decided to move forward on implementing a new funding model, replacing the rounds-based system.
As governments prepare to debate the European Union's overall budget for 2014-2020, European Parliament members and top scientists today warned that any cuts to research and innovation funding will risk the loss of a generation of scientists just when Europe needs them most.
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announced the identification of three potential drug classes for the treatment of neglected tropical diseases through the availability of hundreds of compounds in the public domain.
Greg Perry, a longtime leader in the European generics industry, has been named the new executive director of the Medicines Patent Pool, a cutting-edge Geneva-based group working to increase access to affordable, high-quality medicines for HIV/AIDS patients in low and middle income countries.
In the recent decision on the case “Novartis AG versus Laboratorios LKM SA re cease of use of patent” the Third Chamber of the Federal Civil and Commercial Appellate Court of Argentina set an important precedent in relation to the interpretation of the ius prohibendi of patent holders. In other words, the demarcation of what they can and cannot prohibit.
The Global Fund against AIDS, Tuberculosis and Malaria, a health financing institution focused on the global South, is poised this week to select its next director – from the North. And while the selection process has been conducted in the utmost secrecy, confidential selection documents show that the list is down to four candidates, said to be from Canada, France, the United Kingdom, and the United States.
The industry practice of extending patent protection on pharmaceuticals by obtaining additional patents on other features of the drug ingredients can lead to decades of delay in generic competition, a new study argues.
An outside meeting of experts has prepared a report ahead of this month’s gathering of World Health Organization members hoping to agree on new models for financing research and development for diseases lacking adequate market mechanisms and public policies. These include neglected diseases that predominantly affect poor populations unable to pay high prices needed to defray R&D costs under the existing commercial model.
The government of India has released a set of draft guidelines to be followed in the patenting of traditional knowledge and biological material. Comments are due by 22 November.
Members of the World Trade Organization intellectual property rights committee today launched their first-ever debate on IP and innovation. In addition, least developed countries formally requested an extension of their transition period to enforce WTO rules on IPRs.
The World Trade Organization member committee on the WTO intellectual property agreement meets tomorrow, with a new agenda item on intellectual property and innovation at the request of the United States and Brazil.
India last week saw a landmark public health decision on the evolving role of intellectual property rights in the context of the public interest.